🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

307 results for “Disc Medicine” Clear

  1. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial
  2. Bio-equivalence of Rosuvastatin 10 mg

    Disc Medicine

    Healthy volunteers

    phase 1 other active

    1 trial
  3. Click-cleavable imaging in HER2-positive cancers (CleavHER trial).

    Disc Medicine

    HER2-positive tumors

    phase 1 other active

    1 trial
  4. Coadministration of GA2 Sporozoites With Adjuvants (CoGA)

    Disc Medicine

    Falciparum malaria

    phase 1 other active

    1 trial
  5. Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study

    Disc Medicine

    colorectal liver metastases

    phase 1 other active

    1 trial
  6. DISC-0974

    Disc Medicine

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial
  7. DISC-0974

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  8. DISC-3405

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  9. DISC-3405

    Disc Medicine

    Sickle Cell Disease

    phase 1 small molecule active

    1 trial
  10. Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)

    Disc Medicine

    Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.

    phase 1 other active

    1 trial
  11. Detection of tumor tiSsue in pEritoneal metastases of coLorectal origin using a VEGF-targeted optical fluoresCent imaging tracer during diagnosTic laparoscopy

    Disc Medicine

    peritoneal metastases of colorectal origin

    phase 1 other active

    1 trial
  12. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial
  13. Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.

    Disc Medicine

    Locally advanced rectal cancer

    phase 1 other active

    1 trial
  14. Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

    Disc Medicine

    chronic Hepatitis B

    phase 1 other active

    1 trial
  15. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial
  16. INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

    Disc Medicine

    Patients with malignant peritoneal mesothelioma

    phase 1 other active

    1 trial
  17. INTERACT stomach

    Disc Medicine

    Stomach Cancer with metastasis in the peritoneum

    phase 1 other active

    1 trial
  18. Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors

    Disc Medicine

    locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.

    phase 1 other active

    1 trial
  19. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric cancer

    phase 1 small molecule active

    1 trial
  20. MCA-derived MSC therapy in renal transplant recipients

    Disc Medicine

    Rejection transplanted kidney, BPAR

    phase 1 other active

    1 trial
  21. MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA

    Disc Medicine

    Glioblastoma

    phase 1 other active

    1 trial
  22. Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

    Disc Medicine

    Colorectal cancer, liver metastases

    phase 1 other active

    1 trial
  23. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial
  24. Oxytocine and migraine

    Disc Medicine

    This is a study in healthy volunteers. We will study the trigeminovascular system, which is relevant in the pathophysiology of migraine.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources